Detection of O-glycosylated CA125 by using an electrochemical immunosensor for ovarian cancer diagnosis

Wang, Fu Ming; Huang, Shih Han; Yuan, Chiou‐Chung; Yeh, Chi Tai; Chen, Wei Ling; Wang, Xing Chun; Runprapan, Nattharika; Tsai, Yueh Ju; Chuang, Ya Lin; Su, Chia‐Hung

doi:10.1007/s10800-020-01477-2

Cited by 10 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, Wang et al considered a strategy based on the fact that protein glycosylation (especially O-glycans) provides crucial information for OC diagnosis and developed an EC immunosensor composed of rGO, Au NPs, BSA, thionine chloride (Thic), and two antibodies (anti-CA125 X75 and X306 antibodies). The rGO and Au NPs were used to improve electrical conductivity significantly.…”

Section: Ec Biosensing Of Oncomarkersmentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers for Early Diagnosis of Ovarian Carcinoma

Manasa¹,

Mascarenhas²,

Shetti

et al. 2022

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

The leading cause of gynecological cancer-related morbidity and mortality is ovarian cancer (OC), which is dubbed a silent killer. Currently, OC is a target of intense biomarker research, because it is often not discovered until the disease is advanced. The goal of OC research is to develop effective tests using biomarkers that can detect the disease at the earliest stages, which would eventually decrease the mortality, thereby preventing recurrence. Therefore, there is a pressing need to revisit the existing biomarkers to recognize the potential biomarkers that can lead to efficient predictors for the OC diagnosis. This Perspective covers an update on the currently available biomarkers used in the triaging of OC to gain certain insights into the potential role of these biomarkers and their estimation that are crucial to the understanding of neoplasm progression, diagnostics, and therapy.

show abstract

Section: Ec Biosensing Of Oncomarkersmentioning

confidence: 99%

“…Hence, further investigation concerning these aspects is crucial for its clinical application. Table summarizes the results of the reported research in the development of EC imunosensors for CA125 biomarker determination from 2015 to mid-2022. ,,,− ,− …”

Section: Ec Biosensing Of Oncomarkersmentioning

confidence: 99%